(RT) GLP-3

Name: (RT) GLP-3
SKU: 40968

cGMP Manufacturing

All Instrips products are manufactured in cGMP-compliant facilities with strict adherence to quality standards. Full chain-of-custody documentation ensures traceability, reliability, and reproducibility for research purposes.

Research Applications

Designed for precision research, these peptides support a wide range of experimental protocols. Ideal for laboratory studies requiring consistent, reproducible compound delivery.

Safety & Compliance

All products are intended for research use only. Follow standard lab safety guidelines, including proper protective equipment and waste disposal protocols.

For Research Use Only This product is intended for laboratory and research purposes only. Not for human or animal consumption.

(Also known as LY3437943) is a synthetic peptide and triple agonist of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.

It is currently being researched for its potent effects on metabolic regulation, including enhanced insulin secretion, appetite suppression, increased energy expenditure, and significant body weight reduction in research models.Represents a next-generation approach in the study of multi-receptor agonists for obesity, type 2 diabetes, and related metabolic disorders.

Key Research Areas:

Metabolic and endocrine function
Weight management and energy balance
Glucose homeostasis and insulin sensitivity
Obesity and diabetes disease models
Lipid metabolism and cardiovascular health.

Compound Information 🧪

Molecular Profile

What Is GLP-3 (RT)?

Type Synthetic peptide

CAS Number 2381089-83-2

Molecular Weight 4,731 g/mol

Amino Acids 39

Fatty Acid Chain C20 diacid

PubChem Database

Stability Information

Avoid freeze thaw cycles

Protect from light

Keep refrigerated

❄️Lyophilized (powder)

-20°C•24+ months

💉Reconstituted

2-8°C•~30 days

📚Sources & References

New England Journal of Medicine

Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial

2023•DOI: 10.1056/NEJMoa2301972

Jastreboff AM, et al.

View Source

The Lancet

GLP-3 (RT) for People with Type 2 Diabetes — A Phase 2 Trial

2023

Rosenstock J, et al.

View Source

Nature Medicine

Nature Medicine

GLP-3 (RT) for Metabolic Dysfunction-Associated Steatotic Liver Disease

2024

Sanyal AJ, et al.

View Source

Lancet Diabetes & Endocrinology

Lancet Diabetes & Endocrinology

Effects of GLP-3 (RT) on Body Composition

2025

Coskun T, et al.

View Source

PubMed Central

PubMed Central

Triple Agonism Based Therapies for Obesity

2025

View Source

PubMed Central

GLP-3 (RT) — A Game Changer in Obesity Pharmacotherapy

2025

View Source

PubMed Central

PubMed Central

Efficacy and Safety of GLP-3 (RT) — Systematic Review & Meta-Analysis

2024

View Source

Eli Lilly

Eli Lilly

TRIUMPH-4 Phase 3 Trial Results

2025

View Source

Nature Cell Discovery

Nature Cell Discovery

Structural Analysis of Incretin Receptor Agonists

2024

View Source

PubChem Database

PubChem Database

GLP-3 (RT) Compound Information

View Source

Cllinicaltrials.gov

ClinicalTrials.gov

GLP-3 (RT) Clinical Trials Registry

View Source

⚠️Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.

Weight	.4 oz
Dimensions	.6 × .6 × 1.4 in
Size	10mg, 20mg, 30mg

Reviews

There are no reviews yet.

Be the first to review “(RT) GLP-3”

Reta-20 17755038642687988515679267766637

Related Products

Quick view

(RT) GLP-3